search icon
  • Print
  • ShareThis
  • Text Size
  • Federal Funding for Infectious Diseases Programs


    Today’s investment in ID research; public health and prevention; and development of new drugs, vaccines and diagnostics will pay significant dividends in the future. Such investments can prevent needless deaths, dramatically reduce health care costs, and improve the quality of life for millions of Americans and others around the world.  IDSA supports appropriate funding for domestic and international programs including those at the:

    • National Institute for Allergies and Infectious Diseases 
    • Centers for Disease Control and Prevention  
    • Food and Drug Administration 
    • Health Resources Services Administration 
    • U.S. Agency for International Development 
    • National Institute of Health’s Fogarty International Center 


    IDSA’s funding priorities include antimicrobial resistance; immunizations; drug, vaccine and diagnostics development; and HIV/AIDS and tuberculosis prevention and treatment.


    See also:

    HIVMA Federal Funding

    IDSA's Efforts in Advocating for Appropriate Federal Funding for Infectious Diseases Programs


    IDSA Provides Testimony for Senate Hearing on Ebola Funding (PDF)

    IDSA provided testimony to the Senate Appropriations Committee in support of President Obama's request for emergency funds to deal with the Ebola outbreak.  The Committee solicited stakeholder input ahead of a hearing to discuss the President's request.

    IDSA Provides Testimony on Innovation to the Senate (PDF)

    In preparation for a Senate hearing on the federal role in promoting innovation, IDSA provided testimony on the health and economic gains possible from new public health strategies, vaccines, antibiotics, and rapid diagnostics.

    IDSA Provides Testimony to Congress in Support of Funding for ID Priorities (PDF)

    IDSA provided testimony that stressed the need for federal funding of ID priorities.  The testimony--which touched on areas such as antimicrobial resistance, antibiotic and rapid diagnostic R&D, and immunizations--is the first in a series of advocacy activities that will be taken to engage Congress on the FY15 budget.

    IDSA Senate Testimony on Fiscal Year 2014 Funding for the Department of Health and Human Services (PDF)

    IDSA submitted testimony to the Senate Appropriations Committee regarding FY 2014 funding for the Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA)

    IDSA Engages Senate Finance Committee on Incentives to Spur R&D for New Antibiotics and Diagnostics (PDF)

    IDSA wrote to the co-chairs of the Senate Finance Committee's new working group on business tax policy to urge consideration of incentives, such as permanent tax credits, to spur research and development for new antibiotics and rapid infectious diseases diagnostics.

    IDSA Joins 75 Organizations in Promoting Investments in CDC (PDF)

    IDSA joined with other members of the CDC Coalition to urge Congress to provide $7.8 billion in FY 2016 for the Centers for Disease Control and Prevention.  The recommended funding level would support efforts to address antibiotic resistance and promote global health along with a host of other ID priorities.

    IDSA Joins Coalition Effort to Promote Funding for Preparedness (PDF)

    The Informal Coalition on Biodefense and Public Health Preparedness, which includes IDSA, wrote to appropriators seeking 2016 funding for programs critical to the nation's preparedness for natural and manmade public health threats.

    IDSA Spearheads Advocacy Effort for Funding to Address Antimicrobial Resistance (PDF)

    IDSA was joined by 56 groups in a letter to congressional appropriators that called for full funding of programs put forward to address antimicrobial resistance.  Earlier in the year, President Obama proposed doubling the federal investment to address AR to $1.2 billion spread across CDC, NIH, and other agencies.

    Groups Seek Support for Global TB Activities in Anticipation of FY2014 Funding Bill Release (PDF)

    IDSA joined other stakeholders in a letter to Congress seeking $236 million for USAID's TB programs in FY2014.  The letter discusses the impact of TB around the globe and makes special note of the emergence of multidrug-resistant and extensively drug-resistant TB.  USAID is a central partner in efforts to control TB in the world's 30 most highly burdened countries.

    Community Letter Advocating Robust Global Health Efforts (PDF)

    IDSA joined 53 other organizations to urge lawmakers to maintain its funding commitments to improving health in developing countries, without cutting other broader humanitarian efforts and development or imposing any new policy restrictions.

    TB Coalition Letter for Global and Domestic TB Funding (PDF)

    IDSA joined 16 other organizations to urge lawmakers to strengthen U.S. leadership in the fight against TB as envisioned in the Lantos-Hyde Act and Comprehensive TB Elimination Act by investing in global and domestic TB programs at USAID and CDC.


Average 0 out of 5

| HIVMA | Contact Us

© Copyright IDSA 2015 Infectious Diseases Society of America

Full Site Mobile Site